Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2Lung Neoplasms 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Leukemia, Hairy Cell 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Ependymoma 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma in Situ 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms 1

Interventions

Cisplatin 7Etoposide 5pembrolizumab 4Topotecan 4Pemetrexed 4Gemcitabine 3Carboplatin 3belinostat 2Temozolomide 2RRx-001 2Paclitaxel 2vosaroxin 1vinflunine 1veliparib 1taxane 1sagopilone 1sacituzumab govitecan 1pomalidomide 1lurtotecan 1liposomal doxorubicin 1etoposide phosphate 1enzalutamide 1bemiparin 1belotecan 1apalutamide 1alvocidib 1abiraterone 1Vinorelbine 1Tomography, X-Ray Computed 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × Histamine Antagonists × Clear all
NCT03554473 2025-05-09

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
37 enrolled 19 charts
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡